Definitions
Key terms used in The Precedent's coverage of pharmaceutical regulation, enforcement and compliance.
False Claims Act (FCA)
A federal statute, 31 U.S.C. §§ 3729–3733, that imposes civil liability on persons and companies that defraud federal programs. Violators face treble damages plus civil penalties per false claim. The FCA's qui tam provisions allow private citizens (relators) to sue on the government's behalf and share in recoveries.
Corporate Integrity Agreement (CIA)
A compliance agreement between a company and the HHS Office of Inspector General, typically entered alongside civil settlement of healthcare fraud allegations. CIAs require independent monitoring, compliance reporting, and exclusion risk — usually for five years.
Consent Order
An agreement with a regulatory agency (most often the FTC) that resolves an investigation without an admission of liability. The company agrees to specific conduct restrictions, which are enforceable as court orders. Violation can result in contempt or substantial civil penalties.
Pharmacy Benefit Manager (PBM)
An intermediary that administers prescription drug benefits for health insurers, employers, and government programs. PBMs negotiate rebates from manufacturers, set formularies, and reimburse pharmacies. The three largest — Optum Rx (UnitedHealth), Express Scripts (Cigna), and Caremark (CVS) — collectively process the majority of US retail prescriptions.
Qui Tam
Latin for 'who as well.' A provision of the False Claims Act that allows a private relator (typically a current or former employee) to file a sealed complaint on behalf of the government and receive 15–30% of any recovery. The government may intervene and take over the case, or the relator may proceed independently.
Formulary
A list of drugs covered by a health plan or PBM. Formulary placement — including tier assignment — determines patient out-of-pocket costs and substantially influences prescribing patterns. Formulary decisions are the subject of ongoing FTC and DOJ scrutiny regarding rebate practices.
Medicare Part D
The federal prescription drug benefit, administered through private insurers. Part D plans contract with PBMs to manage drug benefits. The IRA's drug price negotiation provisions apply initially to high-spend Part D drugs.
340B Program
A federal program requiring drug manufacturers to provide outpatient drugs to certain covered entities (hospitals, clinics, FQHCs) at significantly reduced prices. Manufacturers have increasingly restricted 340B discounts to contract pharmacies, generating active litigation and HHS enforcement activity.
IRA (Inflation Reduction Act) Negotiation
Provisions of the Inflation Reduction Act of 2022, codified at 42 U.S.C. § 1320f, authorizing CMS to negotiate prices for high-spend Medicare drugs. Multiple manufacturers challenged the program's constitutionality; all challenges have so far been rejected by federal courts and the Supreme Court.
Open Controversy
In The Precedent's scoring, an open controversy is an enforcement action, investigation, or litigation that has not yet resolved. We track disclosed DOJ civil investigative demands, active state AG suits, and pending FTC proceedings. Open controversies contribute to RedFlag scores based on public disclosures.
